Skip to Content

News & Insights

News & Insights

News & Insights

Perspective Shares Recent Board Placements

Feb 17

Written By Sarah Foster

Sarah Foster

Perspective Group 2H22 Highlights

2022 Year In Review

89bio, Inc. (San Francisco, CA), Vice President, Clinical Development – Wenyan Wang, Ph.D. (former Vice President and Global Leader, Centessa Pharmaceuticals)

Aadi Bioscience (Morristown, NJ), Chief Executive Officer – David Lennon, Ph.D. (former Chief Executive Officer, Satellite Bio)

Acrivon Therapeutics (Watertown, MA), Board Director – Charles Baum, M.D., Ph.D. (President, Founder, Head of Research and Development, Mirati Therapeutics)

Agios Pharmaceuticals (Cambridge, MA), Vice President, Investor Relations and Corporate Communications – Chris Taylor (former Vice President, Investor Relations and Corporate Communications, Codiak BioSciences)

Akamis Bio (Cambridge, MA), Chief Medical Officer - Oliver Rosen, M.D. (former President and Chief Medical Officer, DynamiCure Biotechnology)

ALX Oncology (San Francisco, CA), Chief Executive Officer – Jason Lettmann (former General Partner, Lightstone Ventures)

C4 Therapeutics (Watertown, MA), Board Director – Owen Hughes (former Chief Executive Officer, Cullinan Oncology)

Chinook Therapeutics (Seattle, WA), Chief Commercial Officer – Andrew Oxtoby (former Chief Executive Officer, Aimmune Therapeutics)

Covant Therapeutics (Boston, MA), Chief Executive Officer – Vincent Hennemand (former Chief Operating Officer, Intergalactic Therapeutics)

Editas Medicine (Cambridge, MA), Chief Financial Officer – Erick Lucera (former Chief Financial Officer, AVEO Pharmaceuticals)

Inozyme Pharma (Cambridge, MA), Chief Operating Officer – Matthew Winton, Ph.D. (former Senior Vice President, Head of US MS Franchise, Biogen)

Judo Bio (Cambridge, MA), Chief Scientific Officer – Alfica Sehgal, Ph.D. (former Senior Vice President, Head of Discovery and Translation, CAMP4 Therapeutics)

Korro Bio (Cambridge, MA), Audit Chair – Tim Pearson (Chief Executive Officer, Carrick Therapeutics)

Kymera Therapeutics, Inc. (Watertown, MA), Chief Operating Officer – Jeremy Chadwick, Ph.D. (former Senior Vice President and Head of Global Development Office, R&D, Takeda Pharmaceuticals)

Liberate Bio (Brighton, MA), Chief Executive Officer – Shawn Davis, Ph.D. (former Executive Director, Drug Delivery, AstraZeneca)

Mitochondria eMotion, Inc. (Cambridge, MA), Vice President, Head of Biology – Matthew Jarpe, Ph.D. (former Vice President of Target Biology, Korro Bio, Inc.)

Monte Rosa Therapeutics (Boston, MA), Board Director – Jan Skvarka, Ph.D. (former President and Chief Executive Officer, Trillium Therapeutics)

Mural Oncology (Waltham, MA), Chief Executive Officer – Caroline Loew, Ph.D. (former President and Chief Executive Officer, Glympse Bio)

Mural Oncology (Waltham, MA), Chief Financial Officer – Adam Cutler (former Chief Financial Officer, Q32 Bio)

Mural Oncology (Waltham, MA), Chief Medical Officer – Vicki Goodman, M.D. (former Chief Medical Officer, Exelixis)

Mural Oncology (Waltham, MA), Board Director – Susan Altschuller, Ph.D. (Chief Financial Officer, Cerevel Therapeutics)

Mural Oncology (Waltham, MA), Board Director – Francis Cuss, MB, BChir. (former Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb)

Mural Oncology (Waltham, MA), Board Director – Benjamin Hickey (Chief Commercial Officer, Mirati Therapeutics)

Mural Oncology (Waltham, MA), Board Director – Scott Jackson (former Chief Executive Officer, Celator Pharmaceuticals)

Nested Therapeutics (Cambridge, MA), Board Director – Anna Berkenblit, M.D. (former Senior Vice President and Chief Medical Officer, ImmunoGen, Inc.)

Nested Therapeutics (Cambridge, MA), Chief Business Officer – Tanja Weber (former Chief Business Officer, Epizyme)

Prime Medicine, Inc (Cambridge, MA), Chief Financial Officer - Allan Reine, M.D. (former Chief Financial Officer, Foghorn Therapeutics)

Provention Bio, Inc. (Red Bank, NJ), Board Director – Rita Jain, M.D. (former Executive Vice President and Chief Medical Officer, ChemoCentryx)

Rectify Pharmaceuticals (Cambridge, MA), Chief Operating Officer – Sachiyo Minegishi (former Chief Financial Officer, Akouos)

Remix Therapeutics (Cambridge, MA), Chief Financial Officer – Robert Gagnon (former Chief Financial Officer, Verastem Oncology)

Rome Therapeutics (Cambridge, MA), Chief Financial Officer and Chief Business Officer – Kyle Kuvalanka (former Chief Financial Officer and Chief Operating Officer, Goldfinch Bio)

Scribe Therapeutics (Alameda, CA), Chief Scientific Officer – Aarif Khakoo, M.D. (former Chief Medical Officer and Head of Drug Development, Calico Life Sciences)

Solid Biosciences (Cambridge, MA), Chief Medical Officer – Gabriel Brooks, M.D. (former Executive Director, Pfizer)

Spero Therapeutics (Cambridge, MA), Chief Executive Officer – Sath Shukla (former Chief Financial Officer, Spero Therapeutics)

Tallac Therapeutics (Burlingame, CA), Chief Medical Officer – Kevin Heller, M.D. (former Executive Vice President, Research and Development, Jasper Therapeutics)

Triana Biomedicines (Lexington, MA), Chief Business Officer – Reza Mazhari, Ph.D. (former Head of Search and Evaluation, North America, Business Development and Licensing, Novartis)

Perspective Group LLC | One Broadway Cambridge MA 02142 | Privacy Policy | © 2022 Perspective